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Mutations in the p53 tumor suppressor gene are a common 
finding in many human malignancies. These mutations have 
been shown to inactivate the p53 protein and sometimes 
confer an oncogenic potential to the mutated gene. Type and 
pattern of p53 mutations may give clues to the tumor etiol-
ogy, for example, ultraviolet-induced CC ~ TT and C ~ T 
transitions. Genomic DNA of 16 primary cutaneous mela-
nomas of the superficial and nodular subtype and six mela-
noma metastases were screened for the presence of mutations 
T he product of the wildtype p53 tumor suppressor gene is a sequence-specific DNA-binding protein [1] that can activate transcription in vitro [2] . Wildtype p53 participates in the cellular response to DNA damage l3] and can restore cell-cycle control and inhibit gene 
amplification in cells with mutant ;53 alleles by regulating cell-
cycle progression in the Gl phase l4]. Mutations in the p53 gene 
occur at different sites within highly conserved domains [5 J. Mutant 
p53 genes produce altered protein products that have lost the wild-
type ability to negatively reg~late gene. transcription (loss of func-
tion mutations) [6] and sometimes acqUire an oncogemc phenotype 
(gain of function mutations) [7] . Point mutations in the p53 tumor 
suppressor gene are the single most frequent genetic alterations 
found in human cancer [8] . However, in certain malignancies p53 
mutations are rare or even absent, as in most nonastrocytic brain 
tumors [9] and in testicular neoplasms [10]. In the present study, we 
investigated whether mutant p53 plays a role in the development of 
primary and met~st~tic melanoma, a~d if an ultraviolet-specific ~u­
tational pattern Similar to that exlublted by squamous cell carC1110-
mas of the skin [11] is detectable. 
MATERIALS AND METHODS 
Patients and Samples A total of 22 tumors from 20 patients were ana-
lyzed. Of these, 16 were primary cutaneous melanomas, and six were mela-
noma metastases. All primary tumors were diagnosed as cutaneous melano-
mas of the superficial spreading and the nodular subtypes; no lentigo maligna 
melanomas were included in the study. All primary tumors except one from 
the axilla were located at potentially sun-exposed body sites such as back, 
legs, and chest. Two metastases were from a patient with a primary acral 
lentiginous melanoma, two metastases originated from the same nodular 
primary cutaneous melanoma, one metastasis from a superficial spreading 
melanoma, and one metastasis was from a patient with a primary melanoma 
of the ciliary body. Tumor tissue was collected after surgical resection, or at 
autopsy, frozen in liquid nitrogen, and kept at -80·C until DNA extrac-
tion . The mean age of the patients at the time of sample collection was 52 
years . The primary melanomas ranged between stages II to IV as defined by 
Clark et at (12]. Three tumors were liver metastases, two were lymph node 
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in exons 5 to 8 of the p53 tumor suppressor gene, using the 
polymerase chain reaction and single-strand conformation 
polymorphism analysis, followed by direct DNA sequenc-
ing. We detected no mutations in any of the primary and 
metastatic melanomas in exons 5 to 8 of the p53 tumor sup-
pressor gene. This indicates that, in contrast to skin carcino-
mas, p53 mutations are not operative in the evolution of 
human melanoma.] I'1Vest D ermatol102:819-821, 1994 
metastases, and one was a lung metastasis. Histopathologic diagnosis was 
confirmed on formalin-fixed paraffi nized tumor sections. 
Extraction of DNA Cryostat sections from primary melanomas were 
mounted on uncoated slides. Under microscopic control, the tumor parts 
were separated fr0111 normal tissue and scraped into 1.5-ml reaction tubes. 
Six to twelve 8-,11111 sections per tumor sample were used for DNA extrac-
tion. The material was digested with proteinase K in extraction buffer (50 
mM Tris pH 8.5; 1 mM ethylencdiaminetetraacetic acid, pH 8.0; and 0.5% 
Tween 20) at 37"C overnight, and heated to 95·C for 10 min. DNA 
concentration was estimated by electrophoresis on a 0.8% agarose gel. Meta-
static tumor samples were homogenized in phosphate-buffered saline and 
2 X lysis buffer (Applied Biosystems), treated with proteinase K, and DNA 
precipitated in ethanol after phenol-chloroform extraction. ON A was resus-
pended in H20 and diluted to a final concentration of 100 ng/,ul. 
Polymerase Chain Reaction (PCR) PCR was carried out with 70 to 
150 ng of genomic DNA, 2.0 pmol of each primer, 50 ,uMconcentrations of 
d~oxyn~cleotide triphosphates, 0.8 ,uCi of la -32P] dCTP (Amersham; spe-
Cific actlVlty, 3000CI/mmol), 0.8 ,ul PCR-buffer II (Perkin-Elmer Cetus), 
0.5 umts Taq DNA polymerase (Perkin-Elmer Cetus), and 0.8 to 1.5 mM 
MgClz in a final volume of 8,u1. After addition of 1 0 ,ulmineral oil (Sigma), 
the samples were subjected to 35 cycles (40 cyclcs for exon 6) of denaturation 
(95·C for 60 seconds), annealing (55 'c for 60 seconds for exon 5, 64·C for 
45 seconds for exon 6, 60· C for 60 seconds for exons 7 and 8) and extension 
(70 seconds at n · C) using an automated DNA Thermal Cycler (Perkin-
Elmer Cetus). The following primers were used: 
Exon 5 
Exon 6 
Exon 7 
Exon 8 
5' TTATCTGTTCACTTGTGCCC 3' (A) 
5' ACCCTGGGCAACCAGCCCTGT 3' (B) 
5' ACAGGGCTGGTTGCCCAGGGT 3' (C) 
5' AGTTGCAAACCAGACCT CAG 3' (D) 
5' ACTGGCCTCATCTTGGGCCTGT 3' (E) 
5' CGGTGAACGGT GGGACGTGT 3' (F) 
5' TAAATGGGACAGGTAGGACC 3' (G) 
5' CGTCCTGTTCTTCGCCACCT 3' (H). 
Primers A, B, C,E, F, G, and H were designed from intronsequences (13,14] 
and primer 0 from the respectivc intron/exon border sequence [1 5]. 
Single-Strand Conformation Polymorphism Analysis (SSCP) Pre-
screening of the samples for detection of mutations in the p53 gene was 
performed basically according to the method dcscribed by Orita et al [1 6]. 
Two microliters of the PCR product were mixed with 2,111 0.1 M NaOH and 
9 ,ul of sequencing stop solution (USB). Samples were heated at 95·C for 10 
min and immediately loaded onto a 6% polyacrylamide nondenaturating gel 
containing 10% glycerol. Gels were run at 7 W for 13- 15 h at room tem-
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Figure 1. SSCP gel autoradiography, genomic DNA, p53 exon 7. Sample 
1, malignant melanoma; samples 2, 3, and 7 melanoma metastases; samples 4 
and 5, negative controls with wild-type base sequences; sample 6, positive 
control with heterozygous 3-basepair deletion; nd, nondenaturated DNA. 
Shifted bands suggest presence of mutant DNA in sample 6. 
perature. For autoradiography, dried gels were exposed for 12- 36 h with an 
intensifying screen at -BO·C and the patterns of single- and double-
stranded DNA were analyzed for shifts. Negative controls, with conlirmed 
normal base sequence in the respective exon, were run on each gel. Positive 
controls were sporadically included to check the assay (Fig 1). All samples 
were subjected to at least two PCR-SSCP analyses. 
Direct Sequencing ofPCR Products PCR was performed with 0.3 to 
O.B Jlg of genomic DNA, 10 pmol of each primer, 50 JlM of deoxynucleo-
side triphosphates, 4.0 Jll PCR buffer II, 1.3 mM MgCl2 , and 2.5 units Taq 
DNA polymerase in a final volume of 40 Jll. 
PCR conditions were identical to those described in the PCR-SSCP anal-
ysis. The PCR product was loaded on a 6% polyacrylamide gel, run at 160 V 
for 20 min, stained with ethidium bromide, and visualized under ultraviolet 
light. The specific bands were cut out, eluted in 0.5 M ammonium acetate 
and 1 mM ethylenediaminetetraacetic acid at 37 · C overnight, and precipi-
tated with ethanol. DNA was pelleted, dried and dissolved in 13 Jll H20. 
Sanger dideoxynucleotide sequencing was performed using the sequenc-
ing kit from USB. Four microliters dissolved DNA and 7.5 pmol primer 
were mixed with 2 Jll 5 X reaction buffer (USB) and 1 JlI DMSO, heated at 
95 · C for 5 min, and shock frozen in liquid nitrogen. Analiquot consisting of 
1.5 JlCi [a_32P] dCTP, 20 mM dithiothreitol (USB), and 2.5 units of Se-
quenase version 2.0 (USB) in a total volume of 5 Jll was added and the mix 
immediately brought to reaction in a microwell plate (Nunc) with the four 
termination mixtures (USB) for 10 min at 37· C. The reaction product was 
mixed with 4 Jll stop solution, heated at 90·C for 2 min, and immediately 
loaded onto a 6% polyacrylamide 7 M urea sequencing gel (Gibco) pre-
heated to 50 · C. The gel was run at 1700 V for 2 h. Dried gels were sub-
jected to autoradiography without amplifying screens at room temperature 
for 6 to 15 h. 
RESULTS AND DISCUSSION 
In 16 primary cutaneous melanomas of the superficial spreading and 
the nodular subtype, and in six melanoma metastases, no mutations 
in exons 5 - 8 of the p53 twnor suppressor gene were detected as 
assessed by PCR-SSCP analysis (Figs 1 and 2). In two primary mela-
noma samples, SSCP analysis suggested presence of a mutation in 
exon 7 (Fig 3), but sequence analysis of the whole exon performed 
from 5' and 3' ends did not reveal a mutation. An earlier study on 
p53 gene analysis in melanomas by Volkenandt et al [17] detected a 
point mutation in one of nine melanoma cell lines. The mutation, a 
C - T transition at codon 248, was located at a dipyrimidine site 
known to be a target for ultraviolet-related mutagenesis [18] and 
was subsequently confirmed in archival tissue of the respective pri-
mary tumor. This very low incidence of p53 mutations is compati-
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Figure 2. SSCP gel autoradiography, genomic DNA,p53 exon 6. Samples 
1 to 12, malignant melanoma; sample 13, negative control with wild-type 
base sequence; nd, nondenaturated DNA. Absence of mutations in DNA 
from samples 1 to 12 is suggested by equal migration pattern of single 
stranded DNA. 
ble with the observation that chromosomal abnormalities in mela-
noma usually do not affect the p53 locus on chromosome 17p13 
[19,20]. 
The question whether p53 is involved in the evolution of mela-
noma has so far mainly been addressed by immunohistochemical 
methods, but the results are conflicting. Initial studies reported a 
high incidence of primary melanomas with elevated levels of the 
p53 protein (70 -95%) [21,22], whereas more recent studies found 
an incidence of 4 and 7%, respectively [23,24] . Several other reports 
gave intermediate results ranging from 27 to 58% immunoreactiv-
ity [25-27]. Two laboratories used the monoclonal antibody PAb 
240, which recognizes an epitope characteristic for mutant p53 [28] 
on cryostat cut melanoma sections but also found divergent inci-
dences from 27% [25] to 70% [21]. For metastatic melanoma, the 
results are somewhat less variable, with generally higher values of 
58-93% [21 ,27] p53 immunoreactivity. Although Lassam et at [29] 
found p53 immunoreactivity in 7% of primary melanomas and in 
only 70% of melanoma metastases, another group reported a similar 
incidence of 58% in primary and 67% in metastatic lesions [26]. 
Wild-type and mutant p53 proteins have different half-lives 
[30,31] . Accumulation of p53 to detectable levels is often associated 
with a mutant p53 genotype [32 - 34], whereas wildtype p53 levels 
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Figure 3. SSCP gel autoradiography, genomic DNA, p53 exon 7. Samples 
1 to 5, malignant melanomas; sample 6, negative control with wild-type base 
sequence; nd, nondenaturated DNA. Samples 4 and 5 show a shift in the 
second band from above suggestive for presence of a mutation. Direct se-
quencing analysis revealed only wild-type DNA sequences. 
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in cell nuclei are usually too low for conventional immunohisto-
chemical detection. Positive immunohistochemical reaction to 
anti-p53 antibodies has, therefore, been interpreted as indication for 
a ITlutant p53 gene. However, high p53 expre~sion is not always 
associated with a p53 mutation [35,36]. Certain p53 alteratIOns, 
such as non-sense mutations, can be associated with negative p53 
immunohistochemistry [37]. Recent studies reported p53 immun~­
reactivity in up to 16% ofbenigll nevi [25 - 27], and. in morpholo~l­
cally normal, i.e., in non-transform~d h.uman ke~atlnocytes [38], In 
which the presence of mutant p53 IS highly unlIkely. D.ouble f!53 
deletion, defects in the p53 degradation pathway, adoptIOn of Im-
munohistochemically unrecognizable configurations by m.utant 
p53 proteins, and low protei~ concentr.ations all. may cause pltf~lls 
in the interpretation of p53 Immunohistochemistry [24]. The in-
consistent results of p53 immunohistochemistry in mali~nant mel-
anoma suggest that this method is not suitable for detection C?f F~3 
mutations in this tumor. This does not at all rule out the pOSSlblhty 
that elevated p531evels in melanomas playa role in the pathogen~sis 
of these neoplasms [39], but the mechanisms for the accumulation 
of the wild-type gene product in these tumors is still poorly under-
stood. 
Genetic alterations in melanoma suggestive for ultraviolet in-
volvement have been observed in the N-ras gene [40] at a frequency 
of 12-24% [41]. The mutations are usually in codon 61, located at a 
dipyrimidine site known to be a target for ultraviolet .lightJ42] and 
environmental carcinogens. However, N-ras mutatIOns In mela-
nOITIa are a late phenomenon and seem to affect melanocyte differ-
entiation rather than malignant transformation [41]. Current re-
search focuses on a putative melanoma susceptibility gene located 
on chromosome 9p13-p22 [43]. In conclusion, the absence of p53 
mutations in primary and metastatic cutaneous melanoma demon-
strated in this study suggests that mutational inactivation of the p53 
tuITIor suppressor gene does not confer a growth advantage dur~ng 
melanoma development and is, therefore, not selected for dUrIng 
malignant transformation. 
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